Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s ...
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...
Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback